Research & Development

Revive Therapeutics partners with Complete Phytochemical Solutions to advance research initiatives for psilocybin-based pharmaceutical products

Revive Therapeutics has engaged Complete Phytochemical Solutions, which specialises in unique and complex analyses and formulation development of phytochemicals, to advance the Company’s research and development initiatives of psilocybin-based products for the pharmaceutical market.

5000i – Faster Scale-up of Fermentation Processes

The Kluyver Center for Genomics of Industrial Fermentation in Delft, Holland, is a consortium of several different Universities and Research Centres.

LegoChem Biosciences, Iksuda collaborate to develop antibody-drug conjugates

LegoChem Biosciences, based in Daejeon, South Korea, announced today that it has entered a research collaboration and license agreement with Iksuda Therapeutics (“Iksuda”) for the development of antibody-drug conjugates in oncology.

Starpharma’s SPL7013 shows significant activity against SARS-CoV-2

Starpharma announced that its proprietary VivaGel active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease).

BARDA commits $483m to Moderna for COVID-19 vaccine

Moderna has secured a funding commitment of up to $483m from the US Government agency Biomedical Advanced Research and Development Authority (BARDA) to advance the development of messenger RNA (mRNA) vaccine for novel coronavirus (SARS-CoV-2).

Novartis, TScan collaborate to develop TCR therapies for solid tumours

Novartis has collaborated with TScan Therapeutics for the discovery and development of T cell receptor (TCR) therapies to treat solid tumours.

GSK collaborates with Sanofi to develop COVID-19 vaccine

British drugmaker GlaxoSmithKline (GSK) has joined forces with French pharma company Sanofi for the development of an adjuvanted vaccine for COVID-19 disease.

Alnylam to secure $2bn from Blackstone to advance RNAi medicines

Alnylam Pharmaceuticals has entered into a $2bn strategic financing collaboration with Blackstone to advance the commercial potential of RNA interference (RNAi) therapeutics.

Enzychem Lifesciences announces filing of US provisional patent for EC-18 to treat COVID-19

Enzychem Lifesciences announced that it has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering treating COVID-19 infections and symptoms using EC-18, the Company's lead compound.